Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia

Pharmacotherapy

Volumn 27, Issue 5, 2007, Pages 715-728

  McKenney, James M ^a,c   Sica, Domenic ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c National Clinical Research Inc   (United States)

Author keywords

Coronary heart disease; DHA; Docosahexaenoic acid; Eicosapentaenoic acid; EPA; Hypertriglyceridemia; Omega 3 fatty acids; Pancreatitis

Indexed keywords

AMINOCAPROIC ACID; ATORVASTATIN; DOCOSAHEXAENOIC ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN;

ADD ON THERAPY; ANGINA PECTORIS; BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ERUCTATION; FLU LIKE SYNDROME; FLUSHING; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INFECTION; ISCHEMIC HEART DISEASE; LIVER TOXICITY; PAIN; PRACTICE GUIDELINE; PRESCRIPTION; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SUPPLEMENTATION; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CORONARY DISEASE; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FISH OILS; HUMANS; HYPERTRIGLYCERIDEMIA; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; QUALITY CONTROL; TRIGLYCERIDES;

EID: 34247885908     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.5.715     Document Type: Review

References (74)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: findings from the third national health and nutrition examination survey. JAMA 2002;287:356-9.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-421.
3. Austin M, McKnight B, Edwards K, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 2000;101:2777-82.
4. McKenney J. Dyslipidemias, atherosclerosis, and coronary heart disease. In: Koda-Kimble M, ed. Applied therapeutics: the clinical use of drugs. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
5. Grundy S. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81:B18-25.
6. Athyros VG, Giouleme OI, Nikolaidis NL, et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol 2002;34:472-5.
7. Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003;36:54-62.
8. Fortson MR, Freedman SN, Webster PD III. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995;90:2134-9.
9. Harris W, Ginsberg H, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-91.
10. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-19.
11. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen male study. Circulation 1998;97:1029-36.
12. Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 2005;45:1003-12.
13. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia-safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
14. Robins SJ, Collins D, Wittes JT, et al, for the Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT-a randomized controlled trial. JAMA 2001;285:1585-91.
15. Bezafibrate Infarction Prevention Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study. Circulation 2000;102:21-7.
16. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
17. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study, implications for treatment. Circulation 1992;85:37-45.
18. Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.
19. Keech A, Simes RJ, Barter P, et al, for the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
20. (Erratum in Lancet 2006;368:1415.)
21. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
22. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
23. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76.
24. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26.
25. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004;94:935-8.
26. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-2.
27. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005;165:725-30.
28. Oh R. Practical applications of fish oil (omega-3 fatty acids) in primary care. J Am Board Fam Pract 2005;18:28-36.
29. Bezard J, Blond J, Bernard A, Clouet P. The metabolism and availability of essential fatty acids in animal and human tissues. 1994;34:539-68.
30. Jump D. Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci 2004;41:41-78.
31. Sampath H, Ntambi J. Polyunsaturated fatty acid regulation of gene expression. Nutr Rev 2004;62:333-9.
32. Kris-Etherton P, Harris W, Appel L, for the American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.
33. Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Asses (Summ) 2004;93:1-6.
34. Burdge G. α-Linolenic acid metabolism in men and women: nutritional and biological implications. Curr Opin Clin Nutr Metab Care 2004;7:137-44.
35. Harris W. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989;30:785-807.
36. He K, Song Y, Daviglus M, et al. Accumulated evidence on fish consumption and coronary heart disease mortality. Circulation 2004;109:2705-11.
37. Harper C, Jacobson T. Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. Am J Cardiol 2005;96:1521-9.
38. Burr M, Fehily A, Gilbert J, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-62.
39. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Lancet 1999;354:447-55.
40. (Erratum in Lancet 2001;357:642.)
41. Bucher H, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112:298-304.
42. Reliant Pharmaceuticals, Inc. Omacor (omega-3-acid ethyl esters capsules) prescribing information. Liberty Corner, NJ; 2005.
43. Reliant Pharmaceuticals, Inc. Data on file. Liberty Corner, NJ; 2005.
44. Berge RK, Madsen L, Vaagenes H, Tronstad KJ, Gottlicher M, Rustan AC. In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation. Biochem J 1999;343(pt 1):191-7.
45. Halminski MA, Marsh JB, Harrison EH. Differential effects of fish oil, safflower oil and palm oil on fatty acid oxidation and glycerolipid synthesis in rat liver. J Nutr 1991;121:1554-61.
46. Froyland L, Madsen L, Vaagenes H, et al. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J Lipid Res 1997;38:1851-8.
47. Dagnelie PC, Rietveld T, Swart GR, Stijnen T, van den Berg JW. Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies and triacylglycerol in humans. Lipids 1994;29:41-5.
48. Harris WS, Lu G, Rambjor GS, et al. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr 1997;66:254-60.
49. Chan D, Watts G, Mori T, Batista M, Redgrave T, Beilin L. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr 2003;77:300-7.
50. Bonaa KH, Bjerve KS, Nordoy A. Docosahexaenoic and eicosapentaenoic acids in plasma phospholipids are divergently associated with high density lipoprotein in humans. Arterioscler Thromb 1992;12:675-81.
51. Grundt H, Nilsen D, Hetland O, Aarsland T, Baksaas I, Grande T. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia. J Intern Med 1995;237:249-59.
52. Borthwick L. The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin Drug Invest 1998;15:397-404.
53. Chan D, Watts G, Barrett P, Beilin L, Redgrave T, Mori T. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 2002;51:2377-86.
54. Westphal S, Orth M, Ambrosch A, Osmundsen K, Luley C. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am J Clin Nutr 2000;71:914-20.
55. Calabresi L, Donati D, Pazzucconi F, Sirtori C, Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low-density lipoprotein subclasses. Atherosclerosis 2000;148:387-96.
56. Pownall H, Braucht D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by w-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999;143:285-97.
57. Stalenhoef A, de Graaf J, Wittekoek M, Bredie S, Demacker P, Kastelein J. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low-density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia. Artheriosclerosis 2000;153:129-38.
58. Mackness M, Bhatnagar D, Durrington P, et al. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr 1994;48:859-65.
59. Durrington P, Bhatnagar D, Mackness M, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin-treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001;85:544-8.
60. Eritsland J, Arnesen H, Gronseth K, Fjeld N, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996;77;31-6.
61. Johansen O, Brekke M, Seljeflot I, Abdelnoor M, Arnesen H. N-3 Fatty acids do not prevent restenosis after coronary angioplasty: results from the coronary angioplasty restenosis trial (CART). J Am Coll Cardiol 1999;33:1619-26.
62. McKeone BJ, Osmundsen K, Brauchi D, et al. Alterations in serum phosphatidylcholine fatty acyl species by eicosapentaenoic and docosahexaenoic ethyl esters in patients with severe hypertriglyceridemia. J Lipid Res 1997;38:429-36.
63. Calabresi L, Villa B, Canavesi M, et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 2004;53:153-8.
64. McKenney JM, Swearingen D, Spirito MD, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006;46:785-91.
65. Vanschoonbeek K, Feijge M, Paquay M, et al. Variable hypocoagulant effect of fish oil intake in humans. Arterioscler Thromb Vasc Biol 2004;24:1734-40.
66. Bender N, Kraynak M, Chiquette E, Linn W, Clark G, Bussey H. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thromolysis 1998;5:257-61.
67. U.S. Food and Drug Administration. Pharmaceutical cGMPs for the 21st century. In: Federal register, January 2004. Available from http://www.fda.gov/ohrms/ dockets/95s0316/95s-316-Rpt0272-40-Appendix-D- Reference-F-FDA-vol205.pdf. Accessed February 28, 2006.
68. Krauss R, Eckel R, Howard B, et al. AHA dietary guidelines revision 2000: a statement for healthcare professionals from the nutrition committee of the American Heart Association. Circulation 2000;102:2284-99.
69. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
70. U.S. Department of Agriculture, Agricultural Research Service. USDA national nutrient database for standard reference, release 18, 2005. Nutrient data laboratory home page. Available from http://www.ars.usda.gov/ba/ bhnrc/ndl. Accessed November 11, 2006.
71. U.S. Food and Drug Administration. Compliance program and guidance manual: active pharmaceutical ingredient (API) process inspection. Revision summary. Form FDA 2438g (electronic-09/2003). Rockville, MD: U.S. Food and Drug Administration.
72. Hathcock J. Dietary supplements: how they are used and regulated. J Nutr 2001;131(suppl 3):S1114-17.
73. Center for Food Safety and Applied Nutrition (CFSAN)/ Office of Nutritional Products, Labeling, and Dietary Supplements. Claims that can be made for conventional foods and dietary supplements. Available from http://www.cfsan.fda.gov/~dms/hclaims.html. Accessed November 23, 2005.
74. Center for Food Safety and Applied Nutrition. Omega-3 fatty acids and coronary heart disease. Available from http://www.cfsan.fda.gov/~dms/qhc- sum.html#omega3. Accessed November 15, 2005.